265 related articles for article (PubMed ID: 27494872)
1. Role of micro-RNAs in drug resistance of multiple myeloma.
Abdi J; Jian H; Chang H
Oncotarget; 2016 Sep; 7(37):60723-60735. PubMed ID: 27494872
[TBL] [Abstract][Full Text] [Related]
2. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
Allegra A; Ettari R; Innao V; Bitto A
Cells; 2021 Feb; 10(2):. PubMed ID: 33672466
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer.
Yang W; Ma J; Zhou W; Zhou X; Cao B; Zhang H; Zhao Q; Fan D; Hong L
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1151-1163. PubMed ID: 28838272
[TBL] [Abstract][Full Text] [Related]
6. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
7. The Role of MicroRNAs in the Chemoresistance of Breast Cancer.
Wang J; Yang M; Li Y; Han B
Drug Dev Res; 2015 Nov; 76(7):368-74. PubMed ID: 26310899
[TBL] [Abstract][Full Text] [Related]
8. Role of microRNA in anticancer drug resistance.
Zheng T; Wang J; Chen X; Liu L
Int J Cancer; 2010 Jan; 126(1):2-10. PubMed ID: 19634138
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.
Yang W; Ma J; Zhou W; Cao B; Zhou X; Yang Z; Zhang H; Zhao Q; Fan D; Hong L
Expert Opin Ther Targets; 2017 Nov; 21(11):1063-1075. PubMed ID: 28994330
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
11. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
12. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
[TBL] [Abstract][Full Text] [Related]
13. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Bahrami A; Aledavood A; Anvari K; Hassanian SM; Maftouh M; Yaghobzade A; Salarzaee O; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):774-786. PubMed ID: 28109133
[TBL] [Abstract][Full Text] [Related]
15. Aberrant microRNA expression in multiple myeloma.
Dimopoulos K; Gimsing P; Grønbæk K
Eur J Haematol; 2013 Aug; 91(2):95-105. PubMed ID: 23586898
[TBL] [Abstract][Full Text] [Related]
16. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance-related microRNAs in esophageal cancer.
Hong L; Han Y; Lu Q; Zhang H; Zhao Q; Wu K; Fan D
Expert Opin Biol Ther; 2012 Nov; 12(11):1487-94. PubMed ID: 22827640
[TBL] [Abstract][Full Text] [Related]
18. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
19. The role of miR-34 in cancer drug resistance.
Naghizadeh S; Mohammadi A; Duijf PHG; Baradaran B; Safarzadeh E; Cho WC; Mansoori B
J Cell Physiol; 2020 Oct; 235(10):6424-6440. PubMed ID: 32064620
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs Change the Landscape of Cancer Resistance.
Zhu J; Zhu W; Wu W
Methods Mol Biol; 2018; 1699():83-89. PubMed ID: 29086370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
